COVID-19 associated with cryptococcosis: a scoping review
- PMID: 38361915
- PMCID: PMC10868154
- DOI: 10.1177/20499361241232851
COVID-19 associated with cryptococcosis: a scoping review
Abstract
Background: There is growing evidence of fungal infections associated with COVID-19. The development of cryptococcosis in these patients has been infrequently reported. However, it can be life-threatening.
Objective: To identify cases of COVID-19 patients who developed cryptococcosis and to compare baseline characteristics and management between those who survived and those who died.
Methods: We conducted a scoping review using PubMed, Scopus, Web of Science, and Embase to identify studies that reported patients with COVID-19 and cryptococcosis. No language restriction was applied. Single case reports, case series, and original articles were included. It is important to note that 'n' refers to the total number of individuals with the specified variable.
Results: A total of 58 studies were included. Among these studies, 51 included individual patient data, detailing information on a total of 65 patients, whereas eight studies reported the proportion of cryptococcosis in COVID-19 patients. One study provided both individual and aggregate case information. From individual patient data, the majority were male (73.9%; n = 48) with a median age of 60 years (range: 53-70). Severe COVID-19 and multiple comorbidities, led by arterial hypertension and diabetes mellitus, were frequently reported, but few had classic immunosuppression factors. On the other hand, HIV status, either negative or positive, was reported in just over half of the patients (61.5%; n = 40). Most were admitted to the intensive care unit (ICU) (58.5%; n = 31), received mechanical ventilation (MV) (50.0%; n = 26), and developed disseminated cryptococcosis (55.4%; n = 36). Secondary infection, mainly bacterial, was reported in 19 patients (29.2%). Mortality was 47.7% (n = 31). Of the studies that reported the proportion of cryptococcosis in COVID-19 cases, the majority were descriptive studies published as conference abstracts.
Conclusion: Cryptococcosis in COVID-19 patients has been reported more frequently. However, it is still not as common as other fungal infections associated with COVID-19. Few patients have some classic immunosuppression factors. The factors associated with mortality were male sex, age, ICU admission, MV, secondary infections, and lymphopenia.
Keywords: COVID-19; Cryptococcus; SARS-CoV-2; cryptococcosis; invasive fungal infections; mortality; opportunistic infections; risk factors.
© The Author(s), 2024.
Conflict of interest statement
The authors declare that there is no conflict of interest.
Figures
Similar articles
-
Cryptococcosis among hospitalised patients with COVID-19: A multicentre research network study.Mycoses. 2022 Aug;65(8):815-823. doi: 10.1111/myc.13476. Epub 2022 Jun 19. Mycoses. 2022. PMID: 35657109 Free PMC article.
-
Cryptococcosis complicating diabetes mellitus: a scoping review.Ther Adv Infect Dis. 2021 May 5;8:20499361211014769. doi: 10.1177/20499361211014769. eCollection 2021 Jan-Dec. Ther Adv Infect Dis. 2021. PMID: 33996076 Free PMC article.
-
Cerebral Cryptococcosis Associated with CD4+ T-lymphocytopenia in Non-HIV Patients after SARS-CoV-2 Infection: Case Series in a Specialized Institute in Lima, Peru.Trop Med Infect Dis. 2023 Mar 22;8(3):182. doi: 10.3390/tropicalmed8030182. Trop Med Infect Dis. 2023. PMID: 36977183 Free PMC article.
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
The role of SARS-CoV-2 immunosuppression and the therapy used to manage COVID-19 disease in the emergence of opportunistic fungal infections: A review.Curr Res Biotechnol. 2022;4:337-349. doi: 10.1016/j.crbiot.2022.08.001. Epub 2022 Aug 3. Curr Res Biotechnol. 2022. PMID: 35942223 Free PMC article. Review.
Cited by
-
Update on invasive fungal infections: emerging trends in the incidence of fungal infections in immunosuppressed patients and associated conditions.Ther Adv Infect Dis. 2024 Sep 27;11:20499361241282835. doi: 10.1177/20499361241282835. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 39376744 Free PMC article. No abstract available.
-
Pathogenicity and virulence of Cryptococcus neoformans from an environmental perspective.Virulence. 2025 Dec;16(1):2547090. doi: 10.1080/21505594.2025.2547090. Epub 2025 Aug 14. Virulence. 2025. PMID: 40810603 Free PMC article. Review.
References
-
- Rathore SS, Sathiyamoorthy J, Lalitha C, et al.. A holistic review on Cryptococcus neoformans. Microb Pathog 2022; 166: 105521. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous